概述（Summary）icon

英文全称

Recombinant Human IL5 protein ,N- His Tag

纯度（Purity）

>90% as determined by SDS-PAGE

内毒素（Endotoxin level）

Please contact with the lab for this information.

蛋白构建（Construction）

A DNA sequence encoding the human IL5(Ile20-Ser134) was fused with the N-terminal His Tag

Accession #

P05113

表达宿主（Host）

E.coli

种属（Species）

Homo sapiens (Human)

预测分子量（Predicted Molecular Mass）

12.76kDa

制剂（Formulation）

Supplied as solution form in PBS or lyophilized from PBS .

运输方式（Shipping）

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

稳定性&储存（Stability &Storage）

Use a manual defrost freezer and avoid repeated freeze thaw cycles.
Store at 2 to 8 °C for one week .
Store at -20 to -80 °C for twelve months from the date of receipt.

复溶（Reconstitution）

Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.

电泳图（SDS-PAGE image）icon

背景（Background）icon

背景介绍

Interleukin 5 (IL5) is an interleukin produced by type-2 T helper cells and mast cells. IL-5 is a 115-amino acid (in human, 133 in the mouse) -long TH2 cytokine that is part of the hematopoietic family. Unlike other members of this cytokine family (namely interleukin 3 and GM-CSF), this glycoprotein in its active form is a homodimer. Interleukin-5 has long been associated with the cause of several allergic diseases including allergic rhinitis and asthma, wherein a large increase in the number of circulating, airway tissue, and induced sputum eosinophils have been observed. Given the high concordance of eosinophils and, in particular, allergic asthma pathology, it has been widely speculated that eosinophils have an important role in the pathology of this disease. Drugs that target IL-5 are mepolizumab and reslizumab.

分子别名（Alternative Names）

IL-5,TRF,IL5,Interleukin-5

参考文献（References）

Bergantini, d'Alessandro, Cameli, Bianchi, Sestini, Bargagli, Refini (2020) Personalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab International archives of allergy and immunology () 1-8